WO2001036632A3 - Variants of alternative splicing - Google Patents

Variants of alternative splicing Download PDF

Info

Publication number
WO2001036632A3
WO2001036632A3 PCT/IL2000/000766 IL0000766W WO0136632A3 WO 2001036632 A3 WO2001036632 A3 WO 2001036632A3 IL 0000766 W IL0000766 W IL 0000766W WO 0136632 A3 WO0136632 A3 WO 0136632A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
alternative splicing
nucleic acid
ace
variant
Prior art date
Application number
PCT/IL2000/000766
Other languages
French (fr)
Other versions
WO2001036632A2 (en
Inventor
Zurit Levine
Anat David
Idit Azar
Rami Khosravi
Jeanne Bernstein
Original Assignee
Compugen Ltd
Zurit Levine
Anat David
Idit Azar
Rami Khosravi
Jeanne Bernstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL13297899A external-priority patent/IL132978A0/en
Priority claimed from IL13345599A external-priority patent/IL133455A0/en
Application filed by Compugen Ltd, Zurit Levine, Anat David, Idit Azar, Rami Khosravi, Jeanne Bernstein filed Critical Compugen Ltd
Priority to AU14108/01A priority Critical patent/AU1410801A/en
Publication of WO2001036632A2 publication Critical patent/WO2001036632A2/en
Publication of WO2001036632A3 publication Critical patent/WO2001036632A3/en
Priority to US11/709,841 priority patent/US20070219125A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/15—Peptidyl-dipeptidases (3.4.15)
    • C12Y304/15001—Peptidyl-dipeptidase A (3.4.15.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention concerns novel variants, amino acid and nucleic acid sequences obtained by alternative splicing of known sequences, expression vectors and host cells containing the variants' nucleic acid sequence, and antibodies reactive with the variants' products. The invention also concerns pharmaceutical compositions containing any of the above as well as methods of detection. A preferred example is the angiotensin converting enzyme (ACE) variant.
PCT/IL2000/000766 1999-11-17 2000-11-17 Variants of alternative splicing WO2001036632A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU14108/01A AU1410801A (en) 1999-11-17 2000-11-17 Variants of alternative splicing
US11/709,841 US20070219125A1 (en) 1999-11-17 2007-02-23 Novel thrombospondin-1 polynucleotides encoding variant thrombospondin-1 polypeptides and methods using same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL132978 1999-11-17
IL13297899A IL132978A0 (en) 1999-11-17 1999-11-17 Variants of alternative splicing
IL13345599A IL133455A0 (en) 1999-12-10 1999-12-10 Variants of alternative splicing
IL133455 1999-12-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/709,841 Continuation-In-Part US20070219125A1 (en) 1999-11-17 2007-02-23 Novel thrombospondin-1 polynucleotides encoding variant thrombospondin-1 polypeptides and methods using same

Publications (2)

Publication Number Publication Date
WO2001036632A2 WO2001036632A2 (en) 2001-05-25
WO2001036632A3 true WO2001036632A3 (en) 2002-01-03

Family

ID=26323907

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2000/000766 WO2001036632A2 (en) 1999-11-17 2000-11-17 Variants of alternative splicing

Country Status (2)

Country Link
AU (1) AU1410801A (en)
WO (1) WO2001036632A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811562B2 (en) 2004-12-03 2010-10-12 Schering Corporation Biomarkers for pre-selection of patients for anti-IGF1R therapy

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774209B1 (en) 2000-04-03 2004-08-10 Dyax Corp. Binding peptides for carcinoembryonic antigen (CEA)
EP1506286B1 (en) 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralizing human anti-igfr antibody
ES2321297T3 (en) * 2003-01-08 2009-06-04 Novartis Vaccines And Diagnostics, Inc. STABILIZED WATER COMPOSITIONS THAT INCLUDE INHIBITOR OF THE TISSULAR FACTOR VIA (IVFT) OR VARIANTE OF THE INHIBITOR OF THE TISSUE FACTOR VIA.
WO2005035761A1 (en) * 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
CA2545755A1 (en) 2003-11-12 2005-05-26 Schering Corporation Plasmid system for multigene expression
EP1957527A2 (en) * 2005-11-03 2008-08-20 Liat Mintz Compositions, reagents and kits for and methods of diagnosing, monitoring and treating hormonal imbalance
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc Fibroblast growth factor receptor 3 (fgfr3) binding proteins
HUE034832T2 (en) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-pd-l1 antibodies and their use to enhance t-cell function
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
CN114195884B (en) * 2021-10-27 2024-03-29 禾美生物科技(浙江)有限公司 Recombinant human collagen and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000369A1 (en) * 1983-07-05 1985-01-31 Chiron Corporation Hybrid dna synthesis of epidermal growth factor
WO1990003435A2 (en) * 1988-09-27 1990-04-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nucleic acid coding for the human angiotensine conversion enzyme (ace), and its applications particularly for the in vitro diagnosis of high blood pressure
GB2264948A (en) * 1992-03-13 1993-09-15 Merck & Co Inc Human adenosine receptors
WO1993025677A1 (en) * 1992-06-12 1993-12-23 Garvan Institute Of Medical Research DNA SEQUENCES ENCODING THE HUMAN A1, A2a and A2b ADENOSINE RECEPTORS
WO2001000823A1 (en) * 1999-06-29 2001-01-04 European Molecular Biology Laboratory NOVEL ISOFORMS OF THE HUMAN ESTROGEN RECEPTOR-$g(a)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000369A1 (en) * 1983-07-05 1985-01-31 Chiron Corporation Hybrid dna synthesis of epidermal growth factor
WO1990003435A2 (en) * 1988-09-27 1990-04-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nucleic acid coding for the human angiotensine conversion enzyme (ace), and its applications particularly for the in vitro diagnosis of high blood pressure
GB2264948A (en) * 1992-03-13 1993-09-15 Merck & Co Inc Human adenosine receptors
WO1993025677A1 (en) * 1992-06-12 1993-12-23 Garvan Institute Of Medical Research DNA SEQUENCES ENCODING THE HUMAN A1, A2a and A2b ADENOSINE RECEPTORS
WO2001000823A1 (en) * 1999-06-29 2001-01-04 European Molecular Biology Laboratory NOVEL ISOFORMS OF THE HUMAN ESTROGEN RECEPTOR-$g(a)

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BERNSTEIN K E ET AL: "MOUSE ANGIOTENSIN-CONVERTING ENZYME IS A PROTEIN COMPOSED OF TWO HOMOLOGOUS DOMAINS", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, no. 20, 1989, pages 11945 - 11951, XP002173428, ISSN: 0021-9258 *
BERNSTEIN K E ET AL: "THE ISOLATION OF ANGIOTENSIN-CONVERTING ENZYME CDNA", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 23, 15 August 1988 (1988-08-15), pages 11021 - 11024, XP000095152, ISSN: 0021-9258 *
CHU Y Y ET AL: "Characterization of the rat A2a adenosine receptor gene.", DNA AND CELL BIOLOGY, (1996 APR) 15 (4) 329-37., XP000992998 *
DATABASE EM_EST EMBL; 4 July 1999 (1999-07-04), MARRA, M. ET AL.: "ul01e02.x1 Sugano mouse kidney mkia Mus musculus cDNA clone IMAGE:2064794 3'", XP002173429 *
DATABASE EM_HUM EMBL; 15 December 1995 (1995-12-15), "Human A2a adenosine receptor subtype (ADORA2A) gene", XP002165717 *
FURLONG T J ET AL: "MOLECULAR CHARACTERIZATION OF A HUMAN BRAIN ADENOSINE A2 RECEPTOR", MOLECULAR BRAIN RESEARCH, vol. 15, no. 1/02, 1 September 1992 (1992-09-01), pages 62 - 66, XP000615546, ISSN: 0169-328X *
GELFAND M S ET AL: "ASDB: Database of alternatively spliced genes.", NUCLEIC ACIDS RESEARCH, vol. 27, no. 1, 1 January 1999 (1999-01-01), pages 301 - 302, XP002165716, ISSN: 0305-1048 *
KOIKE S ET AL: "MOLECULAR CLONING AND CHARACTERIZATION OF RAT ESTROGEN RECEPTOR CDNA", NUCLEIC ACIDS RESEARCH, vol. 15, no. 6, 25 March 1987 (1987-03-25), pages 2499 - 2513, XP002026307, ISSN: 0305-1048 *
LU B ET AL: "Estrogen receptor-beta mRNA variants in human and murine tissues.", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 138, no. 1-2, 16 March 1998 (1998-03-16), pages 199 - 203, XP001002992, ISSN: 0303-7207 *
PFEFFER ULRICH ET AL: "Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines.", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 56, no. 1-6, 1996, pages 99 - 105, XP001002991, ISSN: 0960-0760 *
SUGIMURA K ET AL.: "Alternative splicing of the mRNA coding for the human endothelial angiotensin-converting enzyme: a new mechanism for solubilization.", BIOCHEM BIOPHYS RES COMMUN 1998 JUN 18;247(2):466-72., XP002173427 *
WHITE R ET AL: "STRUCTURAL ORGANIZATION AND EXPRESSION OF THE MOUSE ESTROGEN RECEPTOR", MOLECULAR ENDOCRINOLOGY, vol. 1, no. 10, 1987, pages 735 - 744, XP001002989, ISSN: 0888-8809 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811562B2 (en) 2004-12-03 2010-10-12 Schering Corporation Biomarkers for pre-selection of patients for anti-IGF1R therapy

Also Published As

Publication number Publication date
AU1410801A (en) 2001-05-30
WO2001036632A2 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
WO2001075087A8 (en) Subtilisin variants
AUPR107800A0 (en) Peptide and nucleic acid molecule ii
WO2002006457A3 (en) Novel lipase genes
WO2001079462A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
WO2001039722A3 (en) B7-h1, a novel immunoregulatory molecule
WO1997033996A3 (en) Human bikunin
WO2003020932A1 (en) Novel secretory proteins and dna thereof
WO2001079463A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
CA2266319A1 (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
AU6117696A (en) Nucleic acid respiratory syncytial virus vaccines
AU3246300A (en) Polypeptides having galactose oxidase activity and nucleic acids encoding same
CA2315274A1 (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
WO1999067382A3 (en) Angiopoietin-like growth factor sequences
WO2001029222A3 (en) Polypeptides having phospholipase b activity and nucleic acids encoding same
WO2001036632A3 (en) Variants of alternative splicing
WO1995006735A3 (en) Nucleotide sequences for novel protein tyrosine phosphatases
WO2000049158A3 (en) Psa and klk-2 splicing variants
AU9550198A (en) Jmy, a co-activator for p300/cbp, nucleic acid encoding jmy and uses thereof
WO2002012899A3 (en) Peptides presented by cells
AU7489098A (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
WO1997027276A3 (en) Nucleic acids encoding polypeptides having absidia lipase activity
WO2000009693A3 (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
AU3107699A (en) Novel forms of t cell costimulatory proteins, nucleic acid molecules, and uses thereof
WO2001064912A3 (en) Triazine degrading enzymes
CA2176236A1 (en) Tyrosinase-activator protein fusion enzyme

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase